Combined PRF of the Pudendal Nerve With Ganglion Impar Block Effectively Alleviates Pudendal Neuralgia
Launched by PEKING UNIVERSITY PEOPLE'S HOSPITAL · Jun 11, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment for pudendal neuralgia, a condition that causes long-lasting pain in the pelvic area, particularly when sitting. The researchers want to see if a combination of two therapies—pulsed radiofrequency treatment and a ganglion impar block—can help reduce this pain more effectively than traditional treatments or using just one of these methods alone. Since many patients struggle to find relief, this study hopes to provide helpful information for future treatments.
To be eligible for the trial, participants must be between 18 and 80 years old and have been diagnosed with pudendal neuralgia based on specific criteria. This includes having pain in the pudendal nerve area, mainly when sitting, and experiencing relief from this pain after a diagnostic nerve block. Additionally, individuals should have tried other conservative treatments for at least three months without satisfactory results. Participants can expect to receive the new treatment and be monitored for its effectiveness. It’s important to note that individuals with certain conditions, like pelvic cancer or those who are pregnant, will not be able to participate. If you or someone you know fits the criteria and is struggling with this pain, this trial might be an option to consider.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Age between 18 and 80 years old;
- • 2. Diagnosis of pudendal neuralgia meets the Nantes criteria. essential criteria include the following:1)Pain in the territory of the pudendal nerve;2) Pain is predominantly experienced while sitting;3) The pain does not wake the patient at night;4)Pain with no objective sensory impairment;5)Pain relieved by diagnostic pudendal nerve block;
- • 3. Received conservative treatment for more than 3 months, and either had poor response to conservative treatment or intolerable medication side effects.
- • 4. Capable of signing informed consent form.
- Exclusion Criteria:
- • 1. Pain caused by pelvic malignant diseases or autoimmune diseases;
- • 2. Pain caused by pelvic surgery;
- • 3. Taking anticoagulant drugs or having abnormal coagulation function;
- • 4. Pregnancy;
- • 5. Systemic infectious diseases;
- • 6. Inability to complete scale assessments.
About Peking University People's Hospital
Peking University People's Hospital is a leading clinical research institution in China, renowned for its commitment to advancing medical knowledge and improving patient care through innovative clinical trials. Affiliated with Peking University, the hospital integrates cutting-edge research, comprehensive healthcare services, and a multidisciplinary team of experts to facilitate the development of new therapies and medical interventions. With a strong focus on patient safety and ethical standards, Peking University People's Hospital is dedicated to conducting rigorous clinical trials that contribute to the global medical community and enhance the quality of life for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Yiming Liu, MD
Principal Investigator
Peking University People's Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported